Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Free Cash Flow (2018 - 2025)

Historic Free Cash Flow for Whitehawk Therapeutics (WHWK) over the last 8 years, with Q3 2025 value amounting to -$15.4 million.

  • Whitehawk Therapeutics' Free Cash Flow rose 313.07% to -$15.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.0 million, marking a year-over-year decrease of 7011.96%. This contributed to the annual value of -$61.2 million for FY2024, which is 382.02% up from last year.
  • Per Whitehawk Therapeutics' latest filing, its Free Cash Flow stood at -$15.4 million for Q3 2025, which was up 313.07% from -$53.0 million recorded in Q2 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Free Cash Flow peaked at $10.6 million during Q1 2021, and registered a low of -$53.0 million during Q2 2025.
  • Moreover, its 5-year median value for Free Cash Flow was -$13.0 million (2023), whereas its average is -$14.6 million.
  • As far as peak fluctuations go, Whitehawk Therapeutics' Free Cash Flow skyrocketed by 36810.83% in 2021, and later plummeted by 44607.14% in 2025.
  • Over the past 5 years, Whitehawk Therapeutics' Free Cash Flow (Quarter) stood at -$12.5 million in 2021, then increased by 8.71% to -$11.4 million in 2022, then rose by 8.15% to -$10.5 million in 2023, then plummeted by 45.69% to -$15.2 million in 2024, then fell by 0.91% to -$15.4 million in 2025.
  • Its Free Cash Flow stands at -$15.4 million for Q3 2025, versus -$53.0 million for Q2 2025 and -$12.4 million for Q1 2025.